Results
Gland Pharma FY26 Revenue Up 14% with ₹20 Dividend
Gland Pharma reported FY26 consolidated revenue of ₹64,307 million with 14% growth and EBITDA margin expansion to 25.34% from 22.59% in FY25.
The Board recommended a final dividend of ₹20 per equity s